Selection of Itamar’s WatchPAT home sleep apnea diagnostic system underscores the importance and significance of understanding sleep disorders to prevent and manage risk of heart disease and stroke
Recognition that unique biological data collected from WatchPAT will be a valuable addition to the Project 10K database and its predictive medicine goals
CAESAREA, Israel, January 9, 2020 — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that its WatchPAT has been selected for inclusion in the Weizmann Institute’s Project 10K. One of the largest projects of its kind, the 10K Project is a longitudinal study designed to collect lifestyle and clinical data from 10,000 individuals over ten years and aims to use state-of-the-art artificial intelligence technologies to analyze the data in order to generate personalized predictions for disease risk factors. These predictions may improve health outcomes by enabling detection and intervention of treatable medical conditions prior to the onset of symptoms. symptoms.
“The choice of Itamar Medical’s advanced WatchPAT system for the diagnosis of sleep apnea, emphasizes the relationship and significance that the medical and public health communities attribute to the sleep dimension and the impact of sleep quality on the risks of morbidity and heart disease in particular,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical. “We are pleased to be part of Project 10K and to help expand the understanding of the role that sleep apnea plays in multiple aspects of human health.”
As part of the project, Itamar will provide 150,000 WatchPAT tests for the diagnosis and monitoring of sleep apnea. Each subject will undergo a WatchPAT Sleep Apnea diagnostic test once every two years. The WatchPAT’s signals and test results will be used by the team of researchers in developing advanced artificial intelligence-based prediction tools that will reveal connections between sleep apnea and other health conditions that have not previously been known or understood.
Prof. Eran Segal, who is leading Project 10K, said “WatchPAT’s ability to monitor sleep so comprehensively in combination with the multitude of other parameters we are collecting from individuals participating in the project will allow us to find unprecedented new connections between sleep and morbidity.”
Additional information about Project 10K is available at http://www.weizmann.ac.il/sites/Project10K/.
About Itamar Medical Ltd.
Itamar Medical is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory sleep disorders with a focus on the cardiology market. The Company offers a Total Sleep Solution™ to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare costs. Its flagship PAT-based product, the WatchPAT™ device, is a home-use diagnostic device for sleep breathing disorders. It also offers the EndoPAT™ system, an FDA cleared device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.
This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. For example, when we discuss potential WatchPAT test results and the impact these results may have on developing products and the impact of these products, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of our control and actual results, expressed or implied by such forward-looking statements, could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by us in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including our latest Form 20-F which is on file with the SEC and the ISA. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as may be required by law.
The contents of any website of hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of this press release nor is it incorporated herein by reference.
Itamar Medical Company Contact
Itamar Medical Ltd.
Chief Financial Officer
Itamar Medical Investor Relations Contact (U.S.)
Lazar FINN Partners